Patents by Inventor Zhongli Wang

Zhongli Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240083921
    Abstract: Provided are a compound as represented by formula I or a pharmaceutically acceptable salt thereof, and applications of the compound in preparing a medicament for preventing and/or treating a PDE-related disorder.
    Type: Application
    Filed: December 24, 2021
    Publication date: March 14, 2024
    Inventors: Zhongli Wang, Xin Hao, Sang Liu
  • Publication number: 20240018130
    Abstract: The present invention relates to a pyrimidine derivative, a method for preparing same and use thereof in medicine. In particular, the present invention relates to a pyrimidine derivative represented by general formula (I), a method for preparing same and a pharmaceutically acceptable salt thereof as well as use thereof as a therapeutic agent, in particular as a FGFR4 kinase inhibitor, definitions of each substituent in the general formula (I) being the same as those defined in the description.
    Type: Application
    Filed: September 14, 2023
    Publication date: January 18, 2024
    Applicant: Zhejiang Hisun Pharmaceutical Co., Ltd.
    Inventors: Lei Chen, Dongliang Guan, Hua Bai, Jun Gou, Weifeng Zhao, Zhongli Wang, Long Ling, Yutao Ma
  • Patent number: 11827625
    Abstract: The present invention relates to a pyrimidine derivative, a method for preparing same and use thereof in medicine. In particular, the present invention relates to a pyrimidine derivative represented by general formula (I), a method for preparing same and a pharmaceutically acceptable salt thereof as well as use thereof as a therapeutic agent, in particular as a FGFR4 kinase inhibitor, definitions of each substituent in the general formula (I) being the same as those defined in the description.
    Type: Grant
    Filed: March 31, 2021
    Date of Patent: November 28, 2023
    Inventors: Lei Chen, Dongliang Guan, Hua Bai, Jun Gou, Weifeng Zhao, Zhongli Wang, Long Ling, Yutao Ma
  • Publication number: 20230303495
    Abstract: The present invention belongs to the field of medicinal chemistry. Disclosed are a pyridine oxynitride, a preparation method therefor and the use thereof. Specifically, the present invention relates to a series of sodium ion channel blockers with a new structure, a preparation method therefor and the use thereof. The structure thereof is as shown in general formula (I) below. The compounds or a stereoisomer, a racemate, a geometric isomer, a tautomer, a prodrug, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof and a pharmaceutical composition can be used for treating or/and preventing related diseases mediated by a sodium ion channel (NaV).
    Type: Application
    Filed: September 11, 2020
    Publication date: September 28, 2023
    Inventors: Qiong ZHANG, Zhongli WANG, Ming DAI, Fengkai CHENG, Jiu LUO, Yan YE, Jianbiao PENG, Haibing GUO
  • Publication number: 20230026907
    Abstract: The present invention belongs to the field of medicinal chemistry. Disclosed are a pyridine oxynitride, a preparation method therefor and the use thereof. Specifically, the present invention relates to a series of sodium ion channel blockers with a new structure, a preparation method therefor and the use thereof. The structure thereof is as shown in general formula (I) below. The compounds or a stereoisomer, a racemate, a geometric isomer, a tautomer, a prodrug, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof and a pharmaceutical composition can be used for treating or/and preventing related diseases mediated by a sodium ion channel (NaV).
    Type: Application
    Filed: September 11, 2020
    Publication date: January 26, 2023
    Inventors: Qiong ZHANG, Zhongli WANG, Ming DAI, Fengkai CHENG, Jiu LUO, Yan YE, Jianbiao PENG, Haibing GUO
  • Publication number: 20220135560
    Abstract: A pyrazolo[1,5-a]pyridine derivative, and a preparation method and medical use thereof are provided. The pyrazolo[1,5-a]pyridine derivative shown in general formula (I), a preparation method of the derivative, a pharmaceutically acceptable salt of the derivative, and use of the derivative or salt as a therapeutic agent, especially as a rearranged during transfection (RET) inhibitor, are provided.
    Type: Application
    Filed: March 2, 2020
    Publication date: May 5, 2022
    Applicant: CLUES THERAPEUTICS (SHANGHAI) LTD
    Inventors: Suxin ZHENG, Zhongli WANG, Jianping ZHANG, Jun LIU, Quanlin AN, Wenwen ZHAO
  • Publication number: 20210221797
    Abstract: The present invention relates to a pyrimidine derivative, a method for preparing same and use thereof in medicine. In particular, the present invention relates to a pyrimidine derivative represented by general formula (I), a method for preparing same and a pharmaceutically acceptable salt thereof as well as use thereof as a therapeutic agent, in particular as a FGFR4 kinase inhibitor, definitions of each substituent in the general formula (I) being the same as those defined in the description.
    Type: Application
    Filed: March 31, 2021
    Publication date: July 22, 2021
    Applicant: Zhejiang Hisun Pharmaceutical Co., Ltd.
    Inventors: Lei Chen, Dongliang Guan, Hua Bai, Jun Gou, Weifeng Zhao, Zhongli Wang, Long Ling, Yutao Ma
  • Patent number: 11001572
    Abstract: The present invention relates to a pyrimidine derivative, a method for preparing same and use thereof in medicine. In particular, the present invention relates to a pyrimidine derivative represented by general formula (I), a method for preparing same and a pharmaceutically acceptable salt thereof as well as use thereof as a therapeutic agent, in particular as a FGFR4 kinase inhibitor, definitions of each substituent in the general formula (I) being the same as those defined in the description.
    Type: Grant
    Filed: February 25, 2020
    Date of Patent: May 11, 2021
    Inventors: Lei Chen, Dongliang Guan, Hua Bai, Jun Gou, Weifeng Zhao, Zhongli Wang, Long Ling, Yutao Ma
  • Publication number: 20200207745
    Abstract: The present invention relates to a pyrimidine derivative, a method for preparing same and use thereof in medicine. In particular, the present invention relates to a pyrimidine derivative represented by general formula (I), a method for preparing same and a pharmaceutically acceptable salt thereof as well as use thereof as a therapeutic agent, in particular as a FGFR4 kinase inhibitor, definitions of each substituent in the general formula (I) being the same as those defined in the description.
    Type: Application
    Filed: February 25, 2020
    Publication date: July 2, 2020
    Applicant: Zhejiang Hisun Pharmaceutical Co., Ltd.
    Inventors: Lei Chen, Dongliang Guan, Hua Bai, Jun Gou, Weifeng Zhao, Zhongli Wang, Long Ling, Yutao Ma
  • Patent number: 10654836
    Abstract: The present invention relates to a pyrimidine derivative, a method for preparing same and use thereof in medicine. In particular, the present invention relates to a pyrimidine derivative represented by general formula (I), a method for preparing same and a pharmaceutically acceptable salt thereof as well as use thereof as a therapeutic agent, in particular as a FGFR4 kinase inhibitor, definitions of each substituent in the general formula (I) being the same as those defined in the description.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: May 19, 2020
    Assignee: Zhejiang Hisun Pharmaceutical Co., Ltd.
    Inventors: Lei Chen, Dongliang Guan, Hua Bai, Jun Gou, Weifeng Zhao, Zhongli Wang, Long Ling, Yutao Ma
  • Publication number: 20190161476
    Abstract: The present invention relates to a pyrimidine derivative, a method for preparing same and use thereof in medicine. In particular, the present invention relates to a pyrimidine derivative represented by general formula (I), a method for preparing same and a pharmaceutically acceptable salt thereof as well as use thereof as a therapeutic agent, in particular as a FGFR4 kinase inhibitor, definitions of each substituent in the general formula (I) being the same as those defined in the description.
    Type: Application
    Filed: May 19, 2017
    Publication date: May 30, 2019
    Applicant: Zhejiang Hisun Pharmaceutical Co., Ltd.
    Inventors: Lei Chen, Dongliang Guan, Hua Bai, Jun Gou, Weifeng Zhao, Zhongli Wang, Long Ling, Yutao Ma